FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115587079> ?p ?o ?g. }

• W2115587079 endingPage "217" @default.
• W2115587079 startingPage "213" @default.
• W2115587079 abstract "Both mitoxantrone and etoposide have been shown to be active in monotherapy trials of relapsed and refractory acute myelogenous leukemia (AML). This phase II study was undertaken to assess the antitumor activity and toxicity of the combination in refractory and poor-risk AML. The regimen consisted of mitoxantrone, 10 mg/m2/d intravenously (IV), and etoposide, 100 mg/m2/d as short infusion, both on days 1 to 5. Sixty-one patients are evaluable for response and toxicity. Twenty-one were primarily refractory to conventional courses of cytarabine, daunorubicin, and thioguanine; 20 patients had poor-risk first relapse (relapse within 6 months of first complete remission [CR] or relapse under continuous maintenance therapy); 11 had second or subsequent relapses; and nine developed secondary AML after myelodysplastic phase or myelofibrosis. Twenty-six patients (42.6%) attained a CR and seven (11.5%) a partial remission (PR). The median duration of continuous CR was 4.7 months, with a range of 21 days to 14 months, excluding four patients who underwent autologous bone marrow transplantation. Severe myelosuppression was observed in all patients, with a median time to CR of 49 days. Nonhematologic toxicity included stomatitis (mainly grade 1 and 2) in 41 patients, nausea (mainly grade 1 and 2) in 44, infections (mainly grade 3) in 33, and fever of unidentified origin in 11. Other than transient, mild cardiac failure in nine patients, in some of them combined with grade 1 to 2 tachyarrhythmia, no other drug-related cardiac events were observed. Two cases of early death within the first 6 weeks of treatment were registered. Thus, the combination of mitoxantrone and etoposide is a highly active and well-tolerated regimen for refractory and poor-risk AML." @default.
• W2115587079 created "2016-06-24" @default.
• W2115587079 creator A5005594026 @default.
• W2115587079 creator A5014005795 @default.
• W2115587079 creator A5014535165 @default.
• W2115587079 creator A5017002895 @default.
• W2115587079 creator A5041456242 @default.
• W2115587079 creator A5046718005 @default.
• W2115587079 creator A5087568222 @default.
• W2115587079 date "1988-02-01" @default.
• W2115587079 modified "2023-10-01" @default.
• W2115587079 title "Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen." @default.
• W2115587079 cites W1481564836 @default.
• W2115587079 cites W1529957398 @default.
• W2115587079 cites W1591796471 @default.
• W2115587079 cites W1845865637 @default.
• W2115587079 cites W1881046587 @default.
• W2115587079 cites W1934064433 @default.
• W2115587079 cites W1965377737 @default.
• W2115587079 cites W2010964398 @default.
• W2115587079 cites W2017212960 @default.
• W2115587079 cites W2029378155 @default.
• W2115587079 cites W2050146384 @default.
• W2115587079 cites W207118996 @default.
• W2115587079 cites W2096830830 @default.
• W2115587079 cites W2106491226 @default.
• W2115587079 cites W2153943448 @default.
• W2115587079 cites W2286738661 @default.
• W2115587079 cites W2406039517 @default.
• W2115587079 cites W2406677972 @default.
• W2115587079 cites W2411150720 @default.
• W2115587079 cites W2417313707 @default.
• W2115587079 cites W2417817758 @default.
• W2115587079 cites W2418855525 @default.
• W2115587079 cites W2479958022 @default.
• W2115587079 cites W40973501 @default.
• W2115587079 doi "https://doi.org/10.1200/jco.1988.6.2.213" @default.
• W2115587079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3422260" @default.
• W2115587079 hasPublicationYear "1988" @default.
• W2115587079 type Work @default.
• W2115587079 sameAs 2115587079 @default.
• W2115587079 citedByCount "134" @default.
• W2115587079 countsByYear W21155870792012 @default.
• W2115587079 countsByYear W21155870792013 @default.
• W2115587079 countsByYear W21155870792014 @default.
• W2115587079 countsByYear W21155870792015 @default.
• W2115587079 countsByYear W21155870792016 @default.
• W2115587079 countsByYear W21155870792017 @default.
• W2115587079 countsByYear W21155870792018 @default.
• W2115587079 countsByYear W21155870792019 @default.
• W2115587079 countsByYear W21155870792020 @default.
• W2115587079 countsByYear W21155870792021 @default.
• W2115587079 countsByYear W21155870792022 @default.
• W2115587079 countsByYear W21155870792023 @default.
• W2115587079 crossrefType "journal-article" @default.
• W2115587079 hasAuthorship W2115587079A5005594026 @default.
• W2115587079 hasAuthorship W2115587079A5014005795 @default.
• W2115587079 hasAuthorship W2115587079A5014535165 @default.
• W2115587079 hasAuthorship W2115587079A5017002895 @default.
• W2115587079 hasAuthorship W2115587079A5041456242 @default.
• W2115587079 hasAuthorship W2115587079A5046718005 @default.
• W2115587079 hasAuthorship W2115587079A5087568222 @default.
• W2115587079 hasConcept C121332964 @default.
• W2115587079 hasConcept C126322002 @default.
• W2115587079 hasConcept C141071460 @default.
• W2115587079 hasConcept C142424586 @default.
• W2115587079 hasConcept C2776694085 @default.
• W2115587079 hasConcept C2778041864 @default.
• W2115587079 hasConcept C2778119113 @default.
• W2115587079 hasConcept C2778461978 @default.
• W2115587079 hasConcept C2780923524 @default.
• W2115587079 hasConcept C2781413609 @default.
• W2115587079 hasConcept C29730261 @default.
• W2115587079 hasConcept C31760486 @default.
• W2115587079 hasConcept C71924100 @default.
• W2115587079 hasConcept C87355193 @default.
• W2115587079 hasConcept C90924648 @default.
• W2115587079 hasConceptScore W2115587079C121332964 @default.
• W2115587079 hasConceptScore W2115587079C126322002 @default.
• W2115587079 hasConceptScore W2115587079C141071460 @default.
• W2115587079 hasConceptScore W2115587079C142424586 @default.
• W2115587079 hasConceptScore W2115587079C2776694085 @default.
• W2115587079 hasConceptScore W2115587079C2778041864 @default.
• W2115587079 hasConceptScore W2115587079C2778119113 @default.
• W2115587079 hasConceptScore W2115587079C2778461978 @default.
• W2115587079 hasConceptScore W2115587079C2780923524 @default.
• W2115587079 hasConceptScore W2115587079C2781413609 @default.
• W2115587079 hasConceptScore W2115587079C29730261 @default.
• W2115587079 hasConceptScore W2115587079C31760486 @default.
• W2115587079 hasConceptScore W2115587079C71924100 @default.
• W2115587079 hasConceptScore W2115587079C87355193 @default.
• W2115587079 hasConceptScore W2115587079C90924648 @default.
• W2115587079 hasIssue "2" @default.
• W2115587079 hasLocation W21155870791 @default.
• W2115587079 hasLocation W21155870792 @default.
• W2115587079 hasOpenAccess W2115587079 @default.
• W2115587079 hasPrimaryLocation W21155870791 @default.
• W2115587079 hasRelatedWork W2023291141 @default.

• next